GlassScriptPhysician profile
Brooke Meelheim
NPI 1225562630
$4,125.41
in general payments reported to CMS, 2019-2025
21 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what 81% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.95 · 2022: $109 · 2023: $1,053 · 2024: $213 · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,090 · Food and Beverage: $1,093 · Travel and Lodging: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,090.05 |
| Food and Beverage | $1,092.66 |
| Travel and Lodging | $733.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,872.81 | 2023-2025 | Davinci Xi, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $313.07 | 2021-2025 | Lynparza, Enhertu |
| Astellas Pharma US INC | $206.24 | 2025 | Veozah |
| Tempus Ai, INC | $120.08 | 2024-2025 | Xt Cdx |
| Genmab U.S., INC. | $109.31 | 2022 | |
| Merck Sharp & Dohme LLC | $85.53 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Davol INC. | $53.56 | 2024 | Channel Drain |
| Acera Surgical, INC. | $42.56 | 2025 | Restrata Wound Matrix |
| Myriad Genetic Laboratories, INC. | $41.26 | 2024-2025 | Precisetumor |
| Glaxosmithkline, LLC. | $39.79 | 2025 | Zejula, Jemperli |
| Abbvie INC. | $33.62 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $31.53 | 2025 | |
| Daiichi Sankyo INC. | $24.48 | 2023 | Enhertu |
| Caris Mpi, INC. | $23.73 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $23.20 | 2025 | Myfembree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $21.90 | 2025 | |
| Verastem, INC. | $20.24 | 2025 | Avmapki Fakzynja Co-Pack |
| Genentech USA, INC. | $18.84 | 2024 | Perjeta, Phesgo |
| Eisai INC. | $16.83 | 2025 | |
| Heron Therapeutics, INC. | $15.49 | 2024 | Aponvie |
| Channel Medsystems, INC. | $11.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Meelheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.